Forte Biosciences, Inc. (FBRX)
76.99
0.00 (0.00%)
USD |
NASDAQ |
Sep 03, 16:00
Forte Biosciences Cash from Investing (Quarterly) : -147.84M for June 30, 2026
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -147.84M |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | -0.055M |
| June 30, 2025 | 0.00 |
| March 31, 2025 | 36.29M |
| December 31, 2024 | -35.99M |
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | -0.006M |
| December 31, 2023 | -0.016M |
| September 30, 2023 | 10.03M |
| June 30, 2023 | -9.965M |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | 0.00 |
| June 30, 2022 | 0.00 |
| March 31, 2022 | 0.00 |
| December 31, 2021 | 0.00 |
| September 30, 2021 | 0.00 |
| June 30, 2021 | 0.00 |
| Date | Value |
|---|---|
| March 31, 2021 | 0.00 |
| December 31, 2020 | 0.00 |
| September 30, 2020 | -0.001M |
| June 30, 2020 | 3.583M |
| March 31, 2020 | 0.00 |
| December 31, 2019 | -0.089M |
| September 30, 2019 | -0.073M |
| June 30, 2019 | -6.097M |
| March 31, 2019 | 6.097M |
| December 31, 2018 | 0.756M |
| September 30, 2018 | -2.079M |
| June 30, 2018 | 0.794M |
| March 31, 2018 | -3.661M |
| December 31, 2017 | -28.40M |
| September 30, 2017 | 7.574M |
| June 30, 2017 | -10.66M |
| March 31, 2017 | 3.771M |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | 8.282M |
| March 31, 2016 | 3.013M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| argenx SE | -- |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
| Alnylam Pharmaceuticals, Inc. | -363.46M |
| Anika Therapeutics, Inc. | -1.28M |
| Savara, Inc. | 32.60M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -22.70M |
| Cash from Financing (Quarterly) | 161.95M |
| Free Cash Flow | -72.03M |
| Free Cash Flow Per Share (Quarterly) | -0.9544 |
| Free Cash Flow to Equity (Quarterly) | -22.70M |
| Free Cash Flow to Firm (Quarterly) | -22.70M |
| Free Cash Flow Yield | -5.17% |